Intech Investment Management LLC Boosts Position in Guardant Health, Inc. $GH

Intech Investment Management LLC increased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 37.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,187 shares of the company’s stock after purchasing an additional 16,363 shares during the quarter. Intech Investment Management LLC’s holdings in Guardant Health were worth $2,564,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in GH. Driehaus Capital Management LLC purchased a new stake in Guardant Health during the first quarter worth approximately $82,349,000. Invesco Ltd. boosted its holdings in shares of Guardant Health by 100.9% in the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock valued at $119,053,000 after acquiring an additional 1,403,670 shares during the period. Two Sigma Advisers LP boosted its holdings in shares of Guardant Health by 96.7% in the fourth quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock valued at $70,742,000 after acquiring an additional 1,138,300 shares during the period. Iron Triangle Partners LP acquired a new stake in shares of Guardant Health in the first quarter valued at approximately $25,597,000. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in shares of Guardant Health by 202.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 846,749 shares of the company’s stock valued at $36,072,000 after acquiring an additional 566,949 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 2,165 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the transaction, the director owned 851 shares in the company, valued at $46,090.16. The trade was a 71.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the transaction, the chief executive officer owned 2,123,499 shares of the company’s stock, valued at $126,242,015.55. This represents a 12.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 405,788 shares of company stock valued at $23,222,299 over the last 90 days. Insiders own 6.10% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on GH. Mizuho increased their price objective on Guardant Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Friday, June 13th. BTIG Research raised their price target on Guardant Health from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, September 4th. Scotiabank raised their price target on Guardant Health from $57.00 to $60.00 and gave the stock a “sector outperform” rating in a report on Thursday, July 31st. Raymond James Financial raised their price target on Guardant Health from $59.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, July 31st. Finally, Evercore ISI raised Guardant Health to a “strong-buy” rating in a report on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $58.24.

Guardant Health Trading Down 0.2%

Shares of NASDAQ GH opened at $54.79 on Tuesday. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $68.00. The company has a market capitalization of $6.83 billion, a price-to-earnings ratio of -16.36 and a beta of 1.45. The business has a 50 day simple moving average of $53.91 and a 200-day simple moving average of $47.81.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. During the same quarter last year, the firm posted ($0.84) earnings per share. Guardant Health’s revenue was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.